Clinical efficacy of pitavastatin


如何引用文章

全文:

详细

In the review article, anti-hyperlipidemic effects of a new synthetic statin, pitavastatin, are compared with similar effects of other statins. Attention is drawn to the ability of the drug to significantly increase the concentration of high-density lipoprotein cholesterol (by 19.3%!). A number of important, including previously unknown, pleiotropic effects of the drug are considered.

作者简介

D. Aronov

National Medical Research Center of Preventive Medicine of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., заслуженный деятель науки РФ, рук. лаб. 101000, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

M. Bubnova

National Medical Research Center of Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicPM.ru
д-р мед. наук, проф., рук. отд 101000, Russian Federation, Moscow, Petroverigskii per., d. 10, str. 3

参考

  1. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 21: 199-215.
  2. Catapano A.L. Pitavastatin: a different pharmacological profile. Clin Lipidol 2012; 7 (3): 3-9.
  3. Инструкция по медицинскому применению лекарственного препарата Ливазо, РУ ЛП-002855-090215.
  4. Катапано А., Кухарчук В.В., Сергиенко И.В. и др. Питавастатин - современный статин для коррекции дислипидемии и риска сердечно-сосудистых осложнений. Резолюция экспертного совета. Атеросклероз и дислипидемии. 2017; 2: 104-6.
  5. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009; 25: 2755-64.
  6. Warrington S, Nagakawa S, Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men. Clin Drug Investig 2011; 31: 735-43.
  7. Kastelein J.J, Braamskamp M. Pitavastatin: an overview of the LIVES study. Clin Lipidol 2012; 7 (3 Suppl. 1): 25-31.
  8. Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dysli pidaemia. Eur J Prev Cardiol 2013; 20 (1): 40-53.
  9. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009; 4 (3): 291-302.
  10. Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl 2011; 12: 285-8.
  11. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Exp Opin Pharmacother 2010; 11: 817-28.
  12. Kimura K, Shimano H, Yokote K еt al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb 2010; 17: 601-9.
  13. Motomura T, Okamoto M, Kitamura T et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 2009; 16 (5): 546-52.
  14. J-PREDICT Study Group: Japan Prevention Trial of Diabetes by Pitavastatin in Patients with Impaired Glucose Tolerance (J-PREDICT). http://clinicaltrials.gov/ct2/show/NCT00301392.
  15. Chapman M.J, Orsoni A, Robillard P. et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAIL-US studies. Curr Med Res Opin 2014; 1-10.
  16. Huang C, Huang Y, Hsu B. Pitavastatin improves glycated hemoglobin in patients with poorly controlled type 2 diabetes. Diabetes Investig 2016; 7: 769-76.
  17. Drew B.G, Rye K.A, Duffy S.J et al. The emerging role of HDL in glucose metabolism. Nat Rev Endocrinol 2012; 8: 237-45.
  18. Wu X, Yu Z, Su W et al. Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. J Clinic Lipidol 2017. http://creativecommons.org/licenses/by-nc-nd/4.0/
  19. Wang Y, Fu X, Gu X et al. Effects of intensive pitavastatin therapy on glucose control in patients with non-ST elevation acute coronary syndrome. Am J Cardiovasc Dis 2017; 7 (4): 89-96.
  20. Pelliccia F et al. Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivite in patients with coronary artery disease treated with dual antiplatelet therapy. Circ J 2014; 78 (3): 679-84.
  21. Maruyama T, Takada M, Nishibori Y et al. Comparison of preventive effect on cardiovascular events with different statins. The CIRCLE study. Circ J 2011; 75 (8): 1951-9.
  22. Hagiwara N, Kawala-Wayanabe E, Koyanagi R et al. Low - density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38 (29): 2264-76.
  23. Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)’. ClinicalTrials.gov, https://clinicaltrials.gov/ ct2/show/ NCT01042730.
  24. Takano H, Mizuma H, Kuwabara Y et al. оn behalf of the PEARL Study Investigators Effects of Pitavastatin in Japanese Patients With Chronic Heart Failure. The Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-25.
  25. Takayama K, Taki W, Toma N et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study - EPOCH-CAS Study. Cardiovasc Intervent Radiol 2014; 37: 1436-43.
  26. Nakamura T, Obata J.E, Kitta Y et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008; 51: 365-71.
  27. Hattori K, Ozaki Y, Ismail T.F. et al. Impact of statin therapy on plaque characteristics as assessed by Serial OCT, grayscale and integrated backscatter-IVUS. JACC Imag 2012; 5: 169-77.
  28. Hiro T, Kimura T, Morimoto T et al. for the JAPAN-ACS Investigators. Effect of Intensive Statin Therapy on Regression of Coronary Atherosclerosis in Patients With Acute Coronary Syndrome A Multicenter Randomized Trial Evaluated by Volumetric Intravascular Ultrasound Using Pitavastatin Versus Atorvastatin (JAPAN-ACS [Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome] Study). J Am Coll Cardiol 2009; 54: 293-302.
  29. Miayauchi K, Daida H, Morimoto D et al. and Japan-ACS Investigators. Reverse vessel remodeling but not coronary plague regression could predict future cardiovascular events in ACS patients with intensive statin therapy - the extended JAPAN-ACS study. Circ J 2012; 76 (4): 825-32.
  30. Davignon J. Pleiotropic effects of pitavastatin. Br J Clin Pharmacol 2011; 73 (4): 518-35.
  31. Katsumoto M, Shingu T et al. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005; 69 (12): 1547-55.
  32. Sakabe K, Fukuda N, Fukuda Y et al. Comparisons of short-and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008; 125 (1): 136-8.
  33. Yoshida O, Kondo T, Kureishi-Bando Y et al. Pitavastatin, an HMG-CoA reductase inhibitor ameliorates endothelial function in chronic smokers. Circ J 2010; 74 (1): 195-202.
  34. Ohbayashi H, Miyazawa C, Miyamoto K. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009; 16 (4): 490-500.
  35. Umeji K, Umemoto S, Itoh S et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol 2006; 291 (5): H2522-32.
  36. Shinozaki K, Nishio Y, Ayajiki K et al. Pitavastatin restores vascular dysfunction in insulin-resistant state by inhibiting NAD (P) H oxidase activity and uncoupled endothelial nitric oxide synthase-dependent superoxide production. J Cardiovasc Pharmacol 2007; 49 (3): 122-30.
  37. Wang J, Tokoro T, Matsui K et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 2005; 76 (19): 2257-68.
  38. Aoki T, Kataoka H, Ishibashi R et al. Pitavastatin suppresses formation and progression of cerebral aneurysms through inhibition of the nuclear factor kappaB pathway. Neurosurgery 2009; 64 (2): 357-65.
  39. Masamura K, Oida K, Kanehara H et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003; 23: 512-7.
  40. Markle R.A, Han J, Summers B.D. et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 2003; 90: 23-32.

版权所有 © Eco-Vector, 2018

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

##common.cookie##